Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 11, 711 - 712 (2005)
doi:10.1038/nm0705-711
Gleevec casts a pox on poxviruses
Grant McFadden1
- The author is at the University of Western Ontario and the Robarts Research Institute, London, Ontario, N6G 2V4, Canada. e-mail: mcfadden@robarts.ca
Abstract
The tyrosine kinase inhibitor Gleevec, currently used to treat cancers such as chronic myeloid leukemia, can also function as an antiviral drug to treat poxvirus infections (pages 731–739).
Nothing is more certain to catch the attention of clinicians, regulators and biotech investors than the phrase 'off-target market.' Take the case of the current poster child for rational drug development, Gleevec, a small-molecule tyrosine kinase inhibitor currently used to treat chronic myeloid leukemia1, 2, 3.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Research HighlightsNature Biotechnology News and Views (01 Jul 2005)
High-speed mass transit for poxviruses on microtubulesNature Cell Biology News and Views (01 Nov 2001)
RESEARCH
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinasesNature Medicine Article (01 Jul 2005)
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infectionNature Letters to Editor (09 Feb 2006)
See all 5 matches for Research